Loading…
Loading…
WGS does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for WGS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for WGS and 80,000+ other tickers.
See exactly how WGS's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for WGS and 80,000+ other tickers.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights five areas: Scaling genomic interpretation with AI and machine learning: A GeneDx.
Shares of GeneDx Holdings Corp. (NASDAQ: WGS - Get Free Report) were down 5.5% during mid-day trading on Friday. The company traded as low as $66.92 and last traded at $66.3710. Approximately 32,972 shares changed hands during trading, a decline of 96% from the average session volume of 919,692 shares. The stock had previously closed at
LifeMD (NASDAQ: LFMD - Get Free Report) and GeneDx (NASDAQ: WGS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability. Profitability This table compares LifeMD and GeneDx's net margins,
Brookdale Senior Living (NYSE: BKD - Get Free Report) and GeneDx (NASDAQ: WGS - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk. Analyst Ratings This is a breakdown of